Ascentage Pharma Group International

SHSC:6855 Stock Report

Market Cap: HK$12.7b

Ascentage Pharma Group International Management

Management criteria checks 2/4

Ascentage Pharma Group International's CEO is Dajun Yang, appointed in Jan 2009, has a tenure of 15.83 years. total yearly compensation is CN¥4.78M, comprised of 94.7% salary and 5.3% bonuses, including company stock and options. directly owns 0.025% of the company’s shares, worth HK$3.15M. The average tenure of the management team and the board of directors is 6 years and 5.4 years respectively.

Key information

Dajun Yang

Chief executive officer

CN¥4.8m

Total compensation

CEO salary percentage94.7%
CEO tenure15.8yrs
CEO ownership0.02%
Management average tenure6yrs
Board average tenure5.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Dajun Yang's remuneration changed compared to Ascentage Pharma Group International's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-CN¥360m

Mar 31 2024n/an/a

-CN¥643m

Dec 31 2023CN¥5mCN¥5m

-CN¥926m

Sep 30 2023n/an/a

-CN¥902m

Jun 30 2023n/an/a

-CN¥879m

Mar 31 2023n/an/a

-CN¥881m

Dec 31 2022CN¥4mCN¥4m

-CN¥883m

Sep 30 2022n/an/a

-CN¥848m

Jun 30 2022n/an/a

-CN¥812m

Mar 31 2022n/an/a

-CN¥797m

Dec 31 2021CN¥5mCN¥5m

-CN¥782m

Sep 30 2021n/an/a

-CN¥759m

Jun 30 2021n/an/a

-CN¥735m

Mar 31 2021n/an/a

-CN¥706m

Dec 31 2020CN¥4mCN¥4m

-CN¥678m

Sep 30 2020n/an/a

-CN¥922m

Jun 30 2020n/an/a

-CN¥1b

Mar 31 2020n/an/a

-CN¥1b

Dec 31 2019CN¥4mCN¥3m

-CN¥1b

Compensation vs Market: Dajun's total compensation ($USD659.63K) is above average for companies of similar size in the Hong Kong market ($USD487.93K).

Compensation vs Earnings: Dajun's compensation has increased whilst the company is unprofitable.

CEO

Dajun Yang (61 yo)

15.8yrs

Tenure

CN¥4,781,000

Compensation

Dr. Dajun Yang, M.D., Ph D Co-Founded Ascentage Pharma Group International in 2019 and serves as its Chairman and has been its Director since November 17, 2017 and serves as its CEO since July 2018. His...

Leadership Team

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder15.8yrsCN¥4.78m0.025%
HK$ 3.1m
Shaomeng Wang
Co-Founderno dataCN¥1.17mno data
Ming Guo
Co-Founder15.5yrsno datano data
Thomas Knapp
Senior VP & General Counsel5.7yrsno datano data
Yifan Zhai
Chief Medical Officerno datano data0.041%
HK$ 5.2m
Douglas Fang
Senior Vice President of Preclinical Developmentno datano datano data
Jianfeng Wen
Senior Vice President of Pharmaceutical Scienceno datano datano data
Raymond Kmetz
Chief Business Officer5.8yrsno datano data
Yifei Zhu
Chief Commercial Officer1.6yrsno datano data
Cheung Ki Wong
Company Secretary6.3yrsno datano data

6.0yrs

Average Tenure

61yo

Average Age

Experienced Management: 6855's management team is seasoned and experienced (6 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Dajun Yang
Co-Founder7yrsCN¥4.78m0.025%
HK$ 3.1m
Shaomeng Wang
Co-Founder7yrsCN¥1.17mno data
Allen S. Lichter
Chairman of the Clinical Advisory Board1.8yrsno datano data
Paul A. Bunn
Member of Clinical Advisory Boardno datano datano data
David Sidransky
Independent Non-Executive Director3.7yrsCN¥510.00kno data
Jedd D. Wolchok
Member of Clinical Advisory Board3.6yrsno datano data
Arul M. Chinnaiyan
Member of Clinical Advisory Boardno datano datano data
Changqing Ye
Independent Non-Executive Director5.4yrsCN¥502.00kno data
Dazhong Lu
Non-Executive Director6.3yrsCN¥25.00kno data
Wei Ren
Independent Non-Executive Director5.4yrsCN¥502.00kno data
Asher A. Chanan-Khan
Member of Clinical Advisory Board1.8yrsno datano data

5.4yrs

Average Tenure

60yo

Average Age

Experienced Board: 6855's board of directors are considered experienced (5.4 years average tenure).